	Analia dia a	A and a make)
	Application No.	Applicant(s)
Notice of Allowability	09/845,623	AGRAWAL ET AL.
	Examiner	Art Unit
	Traviss C. McIntosh	1623
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85; NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this or other appropriate communical (IGHTS. This application is subje	application. If not included tion will be mailed in due course. THIS
1. \boxtimes This communication is responsive to <u>amendment filed 5/1</u>	<u>1/06</u> .	
2. The allowed claim(s) is/are <u>18-24 and 27</u> .		
3. ☐ Acknowledgment is made of a claim for foreign priority u a) ☐ All b) ☐ Some* c) ☐ None of the:		
1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) including changes required by the attached Examiner Paper No./Mail Date	's Amendment / Comment or in th	e Office action of
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. Notice of References Cited (PTO-892)	5. Notice of Informa	al Patent Application (PTO-152)
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summ	ary (PTO-413),
3. Information Disclosure Statements (PTO-1449 or PTO/SB/	Paper No./Mail 08), 7. 🗌 Examiner's Ame	ndment/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's State	ement of Reasons for Allowance
C. Diological material	9.	

Art Unit: 1623

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance: the prior art is not seen to teach or fairly suggest the use of the claimed immunomodulatory moieties in combination with a CpG dinucleotide for inducing immune responses in mammals. Applicants declaration filed on 8/15/2005 provides results showing that additional immunomodulatory moieties placed in various locations in the 3' or 5' direction respective to the CpG dinucleotide have increasing or decreasing immunomodulatory effects in comparison to the control which lacked the immunomodulatory moiety, and thus shows that these additional agents provide more effect than that of being a stabilizing moiety for the sequence in vivo. One of skill in the art would not have found it obvious to make the compounds in the instant claims and use them as applicants have done. Moreover, the examiner does not think undue experimentation would be required to practice the instant invention, as only routine experimentation would be required to determine which immunomodulatory moieties would have increased or reduced immunostimulatory effect when placed at various positions 3' or 5' of the CpG sequence.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Traviss C. McIntosh whose telephone number is 571-272-0657. The examiner can normally be reached on M-F 9:30-6:00.

Application/Control Number: 09/845,623 Page 3

Art Unit: 1623

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Traviss C. McIntosh III June 19, 2006

Shaojia A. Jiang Art Unit 1623

Supervisory Patent Examiner